Help for bleeding hearts: New research links a third protein to blood-clotting disorders

Studying receptors on the surface of blood platelets, sticky cells that cause blood to clot, has given one Rockefeller researcher new insight into potential causes and treatments for certain cardiovascular diseases. Barry Coller, David Rockefeller Professor and the university's physician-in-chief, has been focusing on a rare disorder known as Glanzmann thrombasthenia, in which platelets lack one of two proteins. Together, the two proteins -- ?IIb and ?3 -- create a cellular receptor that's involved in aggregating blood cells for coagulation; analyzing patients with the disorder previously led Coller to develop a novel therapy for heart-attack and stroke victims that targets this receptor.

In research published in the April 1 issue of Blood, Coller and Beau Mitchell, a research associate in Coller's lab, further characterize the ?IIb?3 receptor by exploring its production and degradation. With colleagues at the Mount Sinai School of Medicine, they found that the production of the receptor, the protein complex of both ?IIb and ?3, is dependent on a third molecule called calnexin. Calnexin plays an important role in protein folding, and the researchers found that it not only helps form the ?IIb?3 receptor complex, but also tags improperly folded ?3 proteins for destruction. Their findings suggest that the factor that controls receptor formation is likely the calnexin cycle; if the two receptor proteins fail to form a correctly folded complex, ?IIb is broken down by the cell. Coller hopes that further study of ?IIb?3 will yield more information about not just Glanzmann thrombasthenia but the synthesis of other receptors like it. These receptors, which are in the integrin superfamily, play a role in many different functions, including embryonic development, inflammation, and tumor growth and metastases, Coller says. "Insights into rare diseases allow us to study and devise strategies for common diseases."


Contact: Kristine Kelly
Rockefeller University

Page: 1

Related biology news :

1. MIT material stops bleeding in seconds
2. Drug can reduce severe bleeding in mothers who have just given birth
3. Carbon monoxide inhibitor controls traumatic bleeding, Tulane University researchers show
4. Gene variants predict bleeding after heart surgery
5. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
6. Saudi Arabias KAUST names WHOI first research partner
7. Multinational research: protecting ecology means understanding people, too
8. Newly created cancer stem cells could aid breast cancer research
9. Carnegie Mellons Peter Adams receives EPA research grant
10. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
11. Innovative tagging technique may help researchers better protect fish stocks

Post Your Comments:

(Date:6/5/2020)... ... , ... Greffex, a pioneering vaccine and gene therapy company based in Houston, ... need for a global perspective to make an impact in a post pandemic world,” ... as an independent, director of the company. , “The Greffex board is excited to ...
(Date:5/28/2020)... ... 2020 , ... Today bioinformatics leader hc1® announced ... lab testing insights and hc1’s exclusive Local Risk Index in a unified CV19 ... employees returning to the workplace. , “Some of the best ways to keep ...
(Date:5/25/2020)... ... May 22, 2020 , ... Oxford Nanopore Technologies is in advanced development ... virus that causes COVID-19. , The LamPORE assay is designed to be ... to very large numbers of samples. Hardware and reagents sit outside current, squeezed ...
Breaking Biology News(10 mins):
(Date:5/30/2020)... YORK (PRWEB) , ... May 29, 2020 , ... ... of Chief Medical Officer 360°, the first newsletter solely dedicated to the unique ... capture a wide range of perspectives on the responsibilities, problem-solving, best practices and ...
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... ... May 21, 2020 , ... Threats to ... long-term harm , Contrary to conventional wisdom that says the coronavirus pandemic will ... companies will emerge from the pandemic commercially weaker, dealing with delays in new ...
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to ... Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory firm. , ... the United States, linking US and Asia Pacific healthcare innovators with capital and investors. ...
Breaking Biology Technology:
Cached News: